Clinical Trials
6 trialsNCT06788912 2026-05-26
MK-3475-01E
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT04165096 2026-05-13
MK-3475-01C
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT05704049 2025-12-29
IZALCO
Sanofi
Phase 2 Active not recruiting
NCT04660799 2023-10-12
A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL)
Hoffmann-La Roche
Phase 2 Completed
NCT02999633 2022-03-21
ISLAY
Sanofi
Phase 2 Terminated
NCT01985126 2018-06-25
An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are Double Refractory to a PI and an IMiD
Janssen Research & Development, LLC
Phase 2 Completed